Five things for pharma marketers to know: Thursday, February 22, 2018

Share this content:

Novo Nordisk diabetes pill delivers in late-stage trial. The company said the tablet, an oral form of semaglutide, demonstrated “significant and superior” improvements in patients' long-term blood sugar, compared to a placebo. (Reuters)

Gilead Sciences and Sangamo Therapeutics have entered into a $3.2 billion partnership to develop engineered cell therapies to treat cancer. Gilead will pay $150 million upfront and $3 billion down the line to use Sangamo's zinc finger nuclease technology platform to develop the therapies. (Endpoints)  

Antidepressants work, according to a large-scale study. Research found 21 antidepressant drugs worked better than placebos, though some were more effective than others. Published in the Lancet, the meta-analysis examined data from 522 trials on a combined 120,000 patients. (Reuters)

Bon Secours Health System to merge with Mercy Health. The two large Catholic hospital systems have a combined annual revenue of $8 billion. The deal is the latest example of hospitals consolidating to compete for patients. (The Baltimore Sun)

Conglomerate Dohmen Company agreed to sell subsidiary Dohmen Life Sciences Services to two New York-based private equity firms. The buyers are J.L.L. Partners and Water Street Healthcare. (MM&M)
Share this content:
Scroll down to see the next article